Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYI 2074

Drug Profile

SYI 2074

Alternative Names: ALT-2074; BXT 51072; SYN-2074

Latest Information Update: 08 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OXIS Therapeutics
  • Developer OXIS Therapeutics; Synvista Therapeutics
  • Class Anti-inflammatories; Anti-ischaemics; Organoselenium compounds; Small molecules
  • Mechanism of Action Antioxidants; Cell adhesion molecule inhibitors; Glutathione peroxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Asthma; Chronic obstructive pulmonary disease; Hepatitis; Plaque psoriasis; Respiratory distress syndrome; Septic shock; Ulcerative colitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Jan 2009 Discontinued - Phase-II for Plaque psoriasis in Israel (Topical)
  • 15 Dec 2008 Phase-II clinical trials in Plaque psoriasis in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top